Over the last few decades, immunotherapy has developed at a rapid rate in the treatment of cancer where neoantigens are the latest breakthrough in tumour immunotherapy. Today, it is still unclear when a cancer vaccine will be made commercially available; what is the latest academic research showing us? What is the industry missing and where are we going?

Join us through a series of inspiring keynote presentations and engaging panel discussions to connect with top pioneers in the space, to discuss the future of cancer immunotherapy and how neoantigens are transforming the field.